China Biotech: Omicron’s new crown mRNA vaccine has received clinical approval from the State Food and Drug Administration

On January 19, the new crown mRNA vaccine developed by Sinopharm Group China Bio-Fu Nuojian Biotechnology (Shanghai) Co., Ltd. for the Omicron variant strain officially obtained the clinical trial approval from the State Drug Administration. Zhongsheng Fu Nuojian has built a pilot research and development platform for mRNA vaccine drugs from design to production in Nanxiang, Shanghai, and an intelligent mRNA vaccine production workshop with an annual production capacity of 2 billion doses, forming a short-term response to emergencies Infectious Diseases Build response capabilities to develop mRNA vaccines and rapidly scale them up. | Related reading (China Biology)

Hu Xi

Regardless of clinical trials or reality, it has been proved that the new crown vaccine of the mRNA technology route is currently the best, not one of them.

It is inevitable and necessary for China to develop mRNA vaccines, both from a scientific and practical perspective. To be clear, science knows no borders, and science cannot have political positions. One thing to insist on is that the mRNA vaccine independently developed by China must be factual and 100% uphold scientific principles and spirits.

Before China’s own mRNA vaccine is successful and promoted, existing mRNA vaccines should not be rejected, because life is priceless and life cannot wait.

This article is reproduced from: https://www.fortunechina.com/jingxuan/26202.htm
This site is only for collection, and the copyright belongs to the original author.